Samir H. Moussa, PhD

Innoviva Specialty Therapeutics, Inc.

Disclosure(s): Innoviva Specialty Therapeutics: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-1532) Surveillance of Eravacycline Against Clinical Pathogens, Including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT